Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis

Rosa Andres-Ejarque¹, Hira Bahadur Ale¹, Katarzyna Grys^{1

2}, Isabella Tosi^{1

2}, Shane Solanky¹, Chrysanthi Ainali^{1

3}, Zeynep Catak^{1

2}, Hemawtee Sreeneebus^{1

2}, Jake Saklatvala⁴, Nick Dand⁴, Emanuele de Rinaldis^{2

5}, Anna Chapman⁶, Frank O Nestle^{1

2

5}, Michael R Barnes⁷, Richard B Warren^#⁸, Nick J Reynolds^#⁹, Christopher E M Griffiths^#⁸, Jonathan N Barker^#^{1

2}, Catherine H Smith^#^{1

2}, Paola Di Meglio^{10

11}; PSORT Consortium

Collaborators, Affiliations

PSORT Consortium:
Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne, Deborah Stocken

¹ St. Johns Institute of Dermatology, Kings College London, London, United Kingdom.
² NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust & King's College London, London, UK.
³ DIGNOSIS Limited, London, UK.
⁴ Department of Medical and Molecular Genetics, Kings College London, London, UK.
⁵ Sanofi, Cambridge, MA, USA.
⁶ Dermatology Department, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UK.
⁷ Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, UK.
⁸ Dermatology Centre, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
⁹ Institute of Translational and Clinical Medicine, Newcastle University Medical School and Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁰ St. Johns Institute of Dermatology, Kings College London, London, United Kingdom. paola.dimeglio@kcl.ac.uk.
¹¹ NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust & King's College London, London, UK. paola.dimeglio@kcl.ac.uk.

^# Contributed equally.

Published Erratum

Rosa Andres-Ejarque et al. Nat Commun. 2021.

. 2021 Dec 16;12(1):7358.

doi: 10.1038/s41467-021-27447-6.

PSORT Consortium:
Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne, Deborah Stocken

¹ St. Johns Institute of Dermatology, Kings College London, London, United Kingdom.
² NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust & King's College London, London, UK.
³ DIGNOSIS Limited, London, UK.
⁴ Department of Medical and Molecular Genetics, Kings College London, London, UK.
⁵ Sanofi, Cambridge, MA, USA.
⁶ Dermatology Department, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UK.
⁷ Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, UK.
⁸ Dermatology Centre, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
⁹ Institute of Translational and Clinical Medicine, Newcastle University Medical School and Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁰ St. Johns Institute of Dermatology, Kings College London, London, United Kingdom. paola.dimeglio@kcl.ac.uk.
¹¹ NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust & King's College London, London, UK. paola.dimeglio@kcl.ac.uk.

^# Contributed equally.

No abstract available

Erratum for

Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Andres-Ejarque R, et al. Nat Commun. 2021 Aug 6;12(1):4741. doi: 10.1038/s41467-021-25066-9. Nat Commun. 2021. PMID: 34362923 Free PMC article.